Liquid chromatographic monitoring of daunorubicin and daunorubicinol in plasma from leukemic patients treated with daunorubicin or the daunorubicin-DNA complex.
Fifteen patients with acute nonlymphocytic leukemia have been randomized for treatment with daunorubicin (1.0--1.5 mg/kg) either as the free drug (for 45 min or 4 h) or as the drug bound to a DNA carrier (for 5--6 h). The correlation between plasma kinetics of daunorubicin and its main metabolite daunorubicinol and the different administration schedules of daunorubicin has been studied by reversed-phase liquid chromatography. Plasma concentration kinetics of daunorubicin as well as the daunorubicin-DNA complex was biphasic in character. Maximum plasma level of daunorubicin was found during the infusion period. Its concentration decreased rapidly when the infusion stopped and was below the detection limit of the analytical method 2--4 h later. The data suggests a slower disposition of the duanorubicin-DNA complex compared with the free drug.
D000818:Animals; D002853:Chromatography, Liquid; D004247:DNA / Q000627:therapeutic use; D003630:Daunorubicin / Q000097:blood* / Q000627:therapeutic use; D006801:Humans; D006900:Hydroxylation; D007700:Kinetics; D007938:Leukemia / Q000097:blood* / Q000188:drug therapy; D008722:Methods
D004247:DNA; D003630:Daunorubicin